A smartwatch algorithm may help detect irregular heart rate – via a pulse notification – indicating possible atrial fibrillation (AF), according to preliminary results of the Apple Heart Study* presented at ACC.19.
The tetracycline omadacycline is not inferior to moxifloxacin when used as empirical monotherapy for hospitalized adults with community-acquired bacterial pneumonia, according to the results of a phase III study.
The humanized immunoglobulin G1 monoclonal antibody risankizumab provided durable clinical efficacy compared with ustekinumab in individuals with moderate-to-severe plaque psoriasis, according to integrated analyses of UltIMMa-1 and 2* presented at AAD 2019.
Multigene testing appears to be feasible in Asian breast cancer patients, resulting in a higher diagnostic yield and detecting pathogenic genetic mutations beyond the usual BRCA1/2 genes, according to a new Singapore study.
A new study from the UK has suggested that patients recently diagnosed with ocular hypertension or open angle glaucoma (OAG) could derive greater benefit from undergoing selective laser trabeculoplasty (SLT) rather than being treated with intraocular pressure-reducing eye drops.
Endogenous testosterone appears to play a significant role in thromboembolism, heart failure (HF) and myocardial infarction (MI), with rates of these conditions higher in men than women, according to a recent study. Existing treatment can control endogenous testosterone, which can be a modifiable risk factor for HF and thromboembolism.
The aminoglycoside plazomicin has demonstrated noninferiority to meropenem, a broad-spectrum carbapenem antibiotic, for treating complicated urinary tract infection (UTI) and acute pyelonephritis, with the former yielding greater microbiologic eradication as reflected by lower incidences of recurrence and relapse, according to data from the phase III EPIC* trial.
A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.